Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Junia Pharma
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Junia Pharma
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
it
en
15 April 2024
THE MERGER BY INCORPORATION INTO PHARMANUTRA S.P.A. OF JUNIA PHARMA S.R.L. AND ALESCO S.R.L. HAS BEEN APPROVED
15 March 2024
PHARMANUTRA S.P.A.: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2023
26 February 2024
Approval of the merger plan
11 January 2024
EURO 100 MILLION IN REVENUE REACHED IN THE YEAR OF ITS 20TH ANNIVERSARY SINCE ESTABLISHMENT
08 January 2024
LOSS OF SME STATUS
21 December 2023
PUBLICATION OF THE 2024 CORPORATE EVENTS CALENDAR
08 November 2023
MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER’S SECURITIES
06 November 2023
BOD APPROVES INTERIM MANAGEMENT REPORT AS AT 30/09/2023
10 October 2023
PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM
03 October 2023
PHARMANUTRA S.P.A.: FIRST SALES ON THE US MARKET
19 September 2023
PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2023
12 September 2023
POLICY FOR THE MANAGEMENT OF THE DIALOGUE WITH ALL SHAREHOLDERS OF PHARMANUTRA S.P.A.
1
2
…
18
>